You are here

Development automated assay-regulators insulin synthesis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DK076510-01
Agency Tracking Number: DK076510
Amount: $200,371.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2006
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
VALA SCIENCES, INC. 11099 N TORREY PINES RD, STE 255
LA JOLLA, CA 92037
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 PATRICK MCDONOUGH
 (858) 646-3162
 PMCDONOUGH@VALASCIENCES.COM
Business Contact
 TINA HUTH
Phone: (858) 200-9520
Email: THUTH@RNDBS.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): We propose to develop an automated screen for small molecules that modulate insulin promoter activity. The assay is based upon a mouse insulinoma, MIN6, that normally expresses insulin mRNA. This cell was engineered to stably contain two cassettes that use a fluorescent reporter protein to monitor insulin promoter activity and a housekeeping gene activity. The secondary assay to be used to confirm the hits will be to verify modulation of endogenous insulin mRNA expression relative to control mRNAs. Like all cultured insulin-producing cells, MIN6 cells produce substantially less insulin mRNA and protein than do normal a-cells in the intact pancreas. Thus, it should be feasible to identify compounds that can either stimulate or suppress insulin production. The assay will be marketed as a tool for researchers to discover small molecule modulators of insulin mRNA synthesis. Such bioactive molecules will be used subsequently to probe the regulatory pathways that control insulin secretion and should contribute to cell-based or pharmacologic treatments for type-I and -II diabetes. Preliminary data indicate that the Insulin promoter-eGFP reporter transgene mimics the activity of the endogenous insulin gene and a pilot screen of 8,000 small synthetic compounds yielded small molecule hits that increased and decreased insulin gene expression. Calculated Z? values of 0.74 for increase and 0.43 for decrease in eGFP were obtained. The proposed Aims are to 1) Optimize the assay and verify its performance in a pilot screen of 50,000 compounds, and 2) Optimize image analysis algorithms and deliver a stand-alone software package to enable investigators to derive reliable numerical data on insulin gene activity from the images. P The project proposes to develop an automated screen for small molecules that modulate insulin promoter activity. The assay will be marketed as a tool for researchers to discover small molecule modulators of insulin mRNA synthesis. Such bioactive molecules will be used subsequently to probe the regulatory pathways that control insulin secretion and should contribute to cell-based or pharmacologic treatments for type-I and -II diabetes.
Preliminary data indicate that the Insulin promoter-eGFP reporter transgene mimics the activity of the endogenous insulin gene and a pilot screen of 8,000 small synthetic compounds yielded small molecule hits that increased and decreased insulin gene expression. Calculated Z' values of 0.74 for increase and 0.43 for decrease in eGFP were obtained. The proposed Aims are to 1) Optimize the assay and verify its performance in a pilot screen of 50,000 compounds, and 2) Optimize image analysis algorithms and deliver a stand-alone software package to enable investigators to derive reliable numerical data on insulin gene activity from the images.
Project Narrative: The project proposes to develop an automated screen for small molecules that modulate insulin promoter activity. The assay will be marketed as a tool for researchers to discover small molecule modulators of insulin mRNA synthesis. Such bioactive molecules will be used subsequently to probe the regulatory pathways that control insulin secretion and should contribute to cell-based or pharmacologic treatments for type-I and -II diabetes

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government